Orexigen obesity drug shows added benefits: studies
NEW YORK (Reuters) - Nearly half of patients who completed 56 weeks of treatment with Orexigen Therapeutics Inc's experimental obesity treatment, Contrave, lost at least 10 percent of their weight in a late-stage study and the drug also appeared to help cholesterol ...